-
Professor Xiaowei Qi: Preferred Neoadjuvant Strategies in HER2-Positive Breast Cancer and Breakthrough Directions in TNBC Immunotherapy
TCbHP as the Preferred Neoadjuvant Strategy in HER2-Positive Breast Cancer Oncology Frontier:In the debate on “optimal neoadjuvant strategies for HER2-positive breast cancer,” you supported the TCbHP regimen. Could you explain…
-
Professors Xuening Ji & Yuhua Song: Rescue Therapy in TNBC—Which Immunotherapy Combination Should Be Preferred?
Key Arguments and Rationale Professor Xuening Ji: Chemotherapy as the Preferred Partner I believe chemotherapy remains the optimal partner for immunotherapy in the rescue treatment of advanced TNBC. These patients…
-
Professors Li Wang & Jianbin Li: Choosing Adjuvant Therapy for Intermediate-Risk HR+ Early Breast Cancer
Weighing the Options Professor Li Wang: Chemotherapy + AI as First Choice In my view, chemotherapy combined with AI remains the preferred adjuvant option for patients with intermediate-risk HR+/HER2− early…
-
Professors Bin Song & Yuan Peng: How Should We Choose CDK4/6 Inhibitors for Adjuvant Endocrine Therapy Intensification?
For patients with hormone receptor–positive (HR+) early breast cancer, when intensifying adjuvant endocrine therapy with a CDK4/6 inhibitor, should abemaciclib or ribociclib be preferred? At the 2025 Summer Breast Cancer Forum · Northern Salon, Professors Bin Song of Shanxi Bethune Hospital and Yuan Peng of Peking University People’s Hospital debated this question during the “Debate”…
-
The 28th CSCO Annual Meeting Opens in Jinan
This September, the city of Jinan welcomed one of China’s most prestigious academic events in oncology. The 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2025) officially opened on the morning of September 11th, gathering experts, clinicians, researchers, and industry representatives from across the country. Multiple academicians and internationally renowned oncologists attended…
-
Professors Ning Xie & Lingzhi Xu: ADC vs. Targeted Therapy + Endocrine Therapy in the Post-CDK4/6i Era
For patients with hormone receptor–positive (HR+) advanced breast cancer who progress after treatment with CDK4/6 inhibitors, should clinicians choose antibody–drug conjugates (ADCs) or a combination of targeted therapy plus endocrine therapy (ET)? At the 2025 Summer Breast Cancer Forum · Northern Salon, the “Debate” session addressed this very question. Professor Ning Xie of Hunan Cancer…
-
Professor Cuizhi Geng: Advancing Standardized Care and Technological Innovation to Drive Homogeneity in Regional Breast Cancer Treatment
The 16th Yan Zhao Breast Cancer Forum was held in Shijiazhuang from August 27–31, 2025. The event was jointly organized by the Breast Cancer Committee of the Hebei Anti-Cancer Association and multiple specialty committees, co-organized by the Beijing Breast Disease Prevention and Treatment Society, and hosted by the Fourth Hospital of Hebei Medical University and…
-
Professor Yunjiang Liu: OPS and MDT as Twin Engines Driving Breast Cancer Treatment into the Era of “Precision Breast-Conservation”
From August 27–31, 2025, the 16th Yan Zhao Breast Cancer Forum was held grandly in Shijiazhuang. The event was jointly organized by the Breast Cancer Committee of the Hebei Anti-Cancer Association and several other specialty committees, co-organized by the Beijing Breast Disease Prevention and Treatment Society, and hosted by the Fourth Hospital of Hebei Medical…
Connecting Medical Expertise through Media